Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

NCT01794299 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions

BIOLOGICAL: ATIR

Sponsor

Kiadis Pharma